Form 4: Spyre Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Scott L Burrows, Chief Financial Officer of Spyre Therapeutics, Inc., sold 25,732 shares of common stock on September 1, 2026.
Summary
- Option exercise/conversion: acquired 7,500 Common Stock at $14.50 ($108,750) on September 1, 2026; holds 105,494 after (Direct).
- Open-market sale: disposed of 900 Common Stock at $86.25 ($77,625) on September 1, 2026; holds 104,594 after (Direct).
- Open-market sale: disposed of 4,384 Common Stock at $87.11 ($381,890) on September 1, 2026; holds 100,210 after (Direct).
- Open-market sale: disposed of 2,016 Common Stock at $88.03 ($177,468) on September 1, 2026; holds 98,194 after (Direct).
- Open-market sale: disposed of 200 Common Stock at $89.04 ($17,808) on September 1, 2026; holds 97,994 after (Direct).
- Open-market sale: disposed of 18,232 Common Stock at $89.35 ($1,629,029) on September 2, 2026; holds 79,762 after (Direct).
- Option exercise/conversion: disposed of 7,500 Stock Option (Right to Buy) on September 1, 2026; holds 337,357 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,283,821 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Scott L Burrows — Officer (Chief Financial Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Option exercise/conversion | Common Stock | 7,500 | $15 | $108.8K | 105,494 |
| 2026-09-01 | Open-market sale | Common Stock | 900 | $86 | $77.6K | 104,594 |
| 2026-09-01 | Open-market sale | Common Stock | 4,384 | $87 | $381.9K | 100,210 |
| 2026-09-01 | Open-market sale | Common Stock | 2,016 | $88 | $177.5K | 98,194 |
| 2026-09-01 | Open-market sale | Common Stock | 200 | $89 | $17.8K | 97,994 |
| 2026-09-02 | Open-market sale | Common Stock | 18,232 | $89 | $1.6M | 79,762 |
| 2026-09-01 | Option exercise/conversion | Stock Option (Right to Buy) | 7,500 | — | — | 337,357 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Option exercise/conversion (7,500 shares) |
| 2026-09-01 | Open-market sale (900 shares) |
| 2026-09-01 | Open-market sale (4,384 shares) |
| 2026-09-01 | Open-market sale (2,016 shares) |
| 2026-09-01 | Open-market sale (200 shares) |
| 2026-09-02 | Open-market sale (18,232 shares) |
| 2026-09-01 | Option exercise/conversion (7,500 shares) |
Keywords
insider transaction, Form 4, SYRE, Spyre Therapeutics, Inc., bearish, Scott L Burrows
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.